admin

admin

Foralumab Shows Imaging Signal in Progressive MS

Tiziana reported November 2 topline results from randomized, double-blind, placebo-controlled Phase 2a INFORM-MS in non-active secondary progressive multiple sclerosis. The 50-µg intranasal foralumab arm showed a TSPO-PET microglial-activation difference versus placebo at 12 weeks…

CTX310 Receives Two FDA RMAT Designations

In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also reported third-quarter…

Bambusa Prices Upsized Immunology IPO

Bambusa Therapeutics priced an upsized US initial public offering on 29 October at 20:15 Eastern: 10,555,555 new shares at $16, for approximately $168.9 million in expected gross proceeds before fees. The shares were scheduled…